386 related articles for article (PubMed ID: 32942535)
1. Distinct TP53 Mutation Types Exhibit Increased Sensitivity to Ferroptosis Independently of Changes in Iron Regulatory Protein Activity.
Thompson LR; Oliveira TG; Hermann ER; Chowanadisai W; Clarke SL; Montgomery MR
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942535
[TBL] [Abstract][Full Text] [Related]
2. Distinct TP53 Mutation Subtypes Differentially Influence Cellular Iron Metabolism.
Clarke SL; Thompson LR; Dandekar E; Srinivasan A; Montgomery MR
Nutrients; 2019 Sep; 11(9):. PubMed ID: 31500291
[TBL] [Abstract][Full Text] [Related]
3. Hot-spot mutants of p53 core domain evince characteristic local structural changes.
Wong KB; DeDecker BS; Freund SM; Proctor MR; Bycroft M; Fersht AR
Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8438-42. PubMed ID: 10411893
[TBL] [Abstract][Full Text] [Related]
4. Differences in Antioxidant and Lipid Handling Protein Expression Influence How Cells Expressing Distinct Mutant TP53 Subtypes Maintain Iron Homeostasis.
Cardona CJ; Hermann ER; Kouplen KN; Hartson SD; Montgomery MR
Cells; 2022 Jun; 11(13):. PubMed ID: 35805147
[TBL] [Abstract][Full Text] [Related]
5.
Shin DY
Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835510
[TBL] [Abstract][Full Text] [Related]
6. The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity.
Xie Y; Zhu S; Song X; Sun X; Fan Y; Liu J; Zhong M; Yuan H; Zhang L; Billiar TR; Lotze MT; Zeh HJ; Kang R; Kroemer G; Tang D
Cell Rep; 2017 Aug; 20(7):1692-1704. PubMed ID: 28813679
[TBL] [Abstract][Full Text] [Related]
7. Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo.
Dibra D; Xiong S; Moyer SM; El-Naggar AK; Qi Y; Su X; Kong EK; Korkut A; Lozano G
Sci Adv; 2024 Feb; 10(7):eadk1835. PubMed ID: 38354236
[TBL] [Abstract][Full Text] [Related]
8. The tumor suppressor protein p53 and the ferroptosis network.
Kang R; Kroemer G; Tang D
Free Radic Biol Med; 2019 Mar; 133():162-168. PubMed ID: 29800655
[TBL] [Abstract][Full Text] [Related]
9. Broadening horizons: the role of ferroptosis in cancer.
Chen X; Kang R; Kroemer G; Tang D
Nat Rev Clin Oncol; 2021 May; 18(5):280-296. PubMed ID: 33514910
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
Vikhanskaya F; Siddique MM; Kei Lee M; Broggini M; Sabapathy K
Clin Cancer Res; 2005 Jun; 11(12):4348-56. PubMed ID: 15958617
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the TP53 gene affected recruitment of 53BP1 protein to DNA lesions, but level of 53BP1 was stable after γ-irradiation that depleted MDC1 protein in specific TP53 mutants.
Suchánková J; Legartová S; Ručková E; Vojtěšek B; Kozubek S; Bártová E
Histochem Cell Biol; 2017 Sep; 148(3):239-255. PubMed ID: 28397142
[TBL] [Abstract][Full Text] [Related]
12. Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer.
Freire Boullosa L; Van Loenhout J; Flieswasser T; De Waele J; Hermans C; Lambrechts H; Cuypers B; Laukens K; Bartholomeus E; Siozopoulou V; De Vos WH; Peeters M; Smits ELJ; Deben C
Redox Biol; 2021 Jun; 42():101949. PubMed ID: 33812801
[TBL] [Abstract][Full Text] [Related]
13. Different TP53 mutations are associated with specific chromosomal rearrangements, telomere length changes, and remodeling of the nuclear architecture of telomeres.
Samassekou O; Bastien N; Lichtensztejn D; Yan J; Mai S; Drouin R
Genes Chromosomes Cancer; 2014 Nov; 53(11):934-50. PubMed ID: 25059482
[TBL] [Abstract][Full Text] [Related]
14. Mutants TP53 p.R273H and p.R273C but not p.R273G enhance cancer cell malignancy.
Li J; Yang L; Gaur S; Zhang K; Wu X; Yuan YC; Li H; Hu S; Weng Y; Yen Y
Hum Mutat; 2014 May; 35(5):575-84. PubMed ID: 24677579
[TBL] [Abstract][Full Text] [Related]
15. Mutation of TP53 Confers Ferroptosis Resistance in Lung Cancer Through the FOXM1/MEF2C Axis.
Peng M; Hu Q; Wu Z; Wang B; Wang C; Yu F
Am J Pathol; 2023 Oct; 193(10):1587-1602. PubMed ID: 37236507
[TBL] [Abstract][Full Text] [Related]
16. Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival.
Mullany LK; Wong KK; Marciano DC; Katsonis P; King-Crane ER; Ren YA; Lichtarge O; Richards JS
Neoplasia; 2015 Oct; 17(10):789-803. PubMed ID: 26585234
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 reactivators protect breast cancer cells from ferroptosis.
Rathnayake DS; Dlamini S; Elkalawozgy K; Tillekeratne LMV; Taylor WR
Cell Biochem Funct; 2024 Jun; 42(4):e4036. PubMed ID: 38778584
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors.
Kim JY; Jung J; Kim KM; Lee J; Im YH
Cancer Med; 2023 Jun; 12(11):12438-12451. PubMed ID: 37081749
[TBL] [Abstract][Full Text] [Related]
19. APR-246 triggers ferritinophagy and ferroptosis of diffuse large B-cell lymphoma cells with distinct TP53 mutations.
Hong Y; Ren T; Wang X; Liu X; Fei Y; Meng S; Han X; Sun C; Shen H; Li L; Qiu L; Qian Z; Zhou S; Zhang H; Wang X
Leukemia; 2022 Sep; 36(9):2269-2280. PubMed ID: 35835991
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53
Polireddy K; Singh K; Pruski M; Jones NC; Manisundaram NV; Ponnela P; Ouellette M; Van Buren G; Younes M; Bynon JS; Dar WA; Bailey JM
Cancer Lett; 2019 Jul; 453():122-130. PubMed ID: 30946870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
